An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 21 Jul 2014
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Amylin Pharmaceuticals; Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2009 Planned number of patients changed from 50 to 58 as reported by ClinicalTrials.gov.
- 19 Jun 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.